title: Tumor lysis syndrome soon after treatment with hydroxyurea followed by nilotinib in two patients with chronic-phase chronic myelogenous leukemia.
abstract: Nilotinib, a second-generation tyrosine kinase inhibitor with 20- to 30-fold greater potency than imatinib, was developed to overcome imatinib intolerance or resistance. Recently, nilotinib has been approved as a first-line treatment for chronic myelogenous leukemia in the US and Japan. Tumor lysis syndrome (TLS) is an extremely rare adverse event that can occur during treatment with nilotinib, with only a few reported cases to date. Herein, we report two patients who developed TLS soon after the start of treatment with nilotinib. While in the first case, which co-presented with underlying mild-to-moderate renal insufficiency due to polycystic kidney disease, the TLS resolved on discontinuation of the drug, the second patient, who had an exceedingly high white blood cell count, presented with disseminated intravascular coagulation and severe liver injury triggered by TLS that developed after the start of nilotinib treatment, and died of multiple organ failure. Therefore, caution is necessary when this drug is used in the first-line setting in patients with renal insufficiency or a high tumor burden.
authors: Department of Hematology, Eiju General Hospital, 2-23-16, Higashi-Ueno, Taito-ku, Tokyo 110-8645, Japan. hua517@yahoo.co.jp
authors: Jian
authors: J
authors: Hua
authors: Yasunobu
authors: Y
authors: Iwaki
authors: Morihiro
authors: M
authors: Inoue
authors: Masao
authors: M
authors: Hagihara
mesh_terms: D000328:Adult; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage / Q000009:adverse effects*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D019384:Nucleic Acid Synthesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects*; D015275:Tumor Lysis Syndrome / Q000097:blood / Q000209:etiology*
chemical_list: D019384:Nucleic Acid Synthesis Inhibitors; D011743:Pyrimidines; C498826:nilotinib; D006918:Hydroxyurea
references: Acta Haematol. 2007;118(4):205-8
references: 18030002
references: J Clin Pharm Ther. 2005 Dec;30(6):623-5
references: 16336296
references: Blood. 2003 Nov 1;102(9):3455-6
references: 14568907
references: Am J Hematol. 2006 Mar;81(3):189-92
references: 16493605
references: Semin Hematol. 2003 Apr;40(2 Suppl 2):21-5
references: 12783371
references: Leuk Res. 2010 Jan;34(1):123-7
references: 19640584
references: Invest New Drugs. 2006 Jan;24(1):85-8
references: 16380835
references: Cancer. 2009 Jun 1;115(11):2482-90
references: 19280591
references: J Clin Oncol. 2010 Jan 20;28(3):392-7
references: 20008621
references: Leuk Res. 2009 Dec;33(12):e234-5
references: 19632720
references: Blood. 2011 Feb 10;117(6):1822-7
references: 21030554
references: Blood. 2009 Jul 9;114(2):261-3
references: 19414863
references: Int J Hematol. 2011 May;93(5):624-632
references: 21523338
references: J Hematol Oncol. 2010 Nov 26;3:47
references: 21108851
references: Br J Haematol. 2011 Jul;154(1):3-13
references: 21554259
references: Br J Haematol. 2004 Oct;127(1):3-11
references: 15384972